import { Helmet } from 'react-helmet-async';
import { Link } from 'react-router-dom';
import Navbar from '@/components/Navbar';
import Footer from '@/components/Footer';
import { BreadcrumbNav } from '@/components/seo/BreadcrumbNav';
import { buildBreadcrumbSchema, buildFAQSchema } from '@/lib/seo/schemas';

const faqItems = [
  {
    question: 'What makes UAE pharmaceutical market research different from other GCC markets?',
    answer:
      'The UAE has a tripartite regulatory structure — DHA (Dubai), DOH (Abu Dhabi, formerly HAAD), and MOHAP (federal and Northern Emirates) — meaning formulary access, pricing approval, and prescribing authority differ significantly across emirates. A drug approved on the DHA formulary does not automatically gain DOH listing. Abu Dhabi operates mandatory insurance through Daman/HAAD with its own benefit table and prior-authorisation requirements, while Dubai requires mandatory health insurance for all residents since 2016. Research designs that ignore this emirate-level segmentation produce misleading findings. BioNixus stratifies sampling across all three regulatory zones and recruits from both public hospital networks (Ministry of Health facilities, Seha in Abu Dhabi, DHA-managed hospitals in Dubai) and private sector institutions (Mediclinic, Cleveland Clinic Abu Dhabi, Aster DM Healthcare, NMC Health) to capture the full UAE prescribing landscape.',
  },
  {
    question: 'Which therapy areas does BioNixus specialise in for UAE pharma research?',
    answer:
      'BioNixus has conducted primary research in UAE across oncology (Tawam Hospital network in Al Ain, Burjeel Medical City, American Hospital Dubai), diabetes and metabolic disease (approximately 19% adult prevalence in UAE per IDF 2023 estimates — among the highest globally), cardiovascular disease, respiratory conditions (asthma, COPD, ILD), rare diseases and orphan drugs, biosimilars, neurology, and ophthalmology (high cataract and retinal disease burden). UAE\'s cosmopolitan specialist workforce — approximately 70% of physicians are expatriates from India, Egypt, Jordan, the Philippines, and Western countries — means that therapy area familiarity spans both GCC-endemic conditions and internationally prevalent disease profiles. Our field team recruits from DHA-registered, DOH-licensed, and MOHAP-registered HCP pools to ensure verifiable participant credentials across all emirates.',
  },
  {
    question: 'How does the expatriate HCP majority affect research design in UAE?',
    answer:
      'The UAE physician workforce is approximately 70% expatriate, with Indian, Egyptian, Jordanian, and Western-trained doctors representing the majority of prescribers. This creates research design implications that global pharma teams frequently underestimate. First, language: many UAE physicians prefer to conduct interviews in English, particularly Indian and Western-trained doctors, even if they work in Arabic-speaking institutional settings. Arabic-first instruments designed for Saudi Arabia or Kuwait may alienate or confuse UAE respondents. BioNixus uses bilingual instruments with language-preference screening at recruitment stage. Second, clinical training background: a diabetologist trained in India may have different prescribing defaults from one trained in Egypt or Germany, even while practising at the same Dubai hospital. Quota controls by nationality or training background are sometimes necessary for insight accuracy. Third, prescribing authority: expatriate physicians in UAE public hospitals sometimes operate under formulary and procurement rules set by UAE national administrators — understanding this hierarchy prevents conflation of prescribing preference with actual prescribing behaviour.',
  },
  {
    question: 'What does a typical UAE pharma market research programme cost and how long does it take?',
    answer:
      'A focused HCP online survey (75 respondents, two emirates, one specialty) typically costs between AED 80,000 and AED 165,000 ($22,000–$45,000 USD) and takes 5–7 weeks from briefing to final report. An in-depth interview series (10–12 specialist KOLs across Dubai and Abu Dhabi) ranges from AED 65,000 to AED 115,000 ($18,000–$32,000 USD) and takes 4–6 weeks. An advisory board with 8–10 UAE specialists costs AED 75,000–AED 165,000 ($20,000–$45,000 USD) and can be deployed within 4–6 weeks. Brand tracking studies (two waves) typically run AED 200,000–AED 440,000 ($55,000–$120,000 USD) over a 6–12 week window per wave. Market access payer research — targeting DHA Health Economics Department, DOH formulary committee members, and HAAD insurance decision-makers — commands a premium given the restricted audience and runs AED 110,000–AED 220,000 ($30,000–$60,000 USD).',
  },
  {
    question: 'How are UAE HCP respondents verified for research validity?',
    answer:
      'BioNixus verifies UAE HCP respondents through a three-stage process. First, licence number validation: all UAE physicians must hold a DHA licence (Dubai), DOH licence (Abu Dhabi), or MOHAP licence (other emirates). We cross-reference self-reported licence numbers against publicly accessible regulatory databases before scheduling. Second, institutional affiliation confirmation: we verify current hospital or clinic affiliation through a combination of direct telephone confirmation and institutional directory cross-check. Third, specialty qualification confirmation: for specialist panels, we require documentary evidence of specialty training or board certification, particularly for oncology, cardiology, and neurology where general practitioners may overstate specialty experience on screeners. This three-stage process eliminates fraudulent completions and ensures that quota cells contain genuinely qualified respondents.',
  },
  {
    question: 'Can BioNixus support payer and market access research in UAE?',
    answer:
      'Yes. UAE market access research is one of BioNixus\'s core service areas. We conduct qualitative interviews with DHA Health Economics Department officials (responsible for Dubai formulary listing), DOH formulary committee advisors (Abu Dhabi drug benefit coverage), HAAD insurance specialists, and major private insurer representatives (Daman, AXA Gulf, MetLife, Allianz Care). We also conduct quantitative surveys with hospital pharmacy directors and P&T committee members to measure formulary listing priority drivers, willingness-to-pay thresholds, and evidence requirements for biosimilar or novel drug access. For the Abu Dhabi market specifically, outcomes-based contracting pilots (risk-sharing between manufacturers and Daman/HAAD) are an emerging area where BioNixus provides payer perspective research to support value dossier development and negotiation positioning.',
  },
];

const jsonLd = [
  {
    '@context': 'https://schema.org',
    '@type': 'Service',
    name: 'Pharmaceutical Market Research UAE',
    serviceType: 'Pharmaceutical and healthcare market research in the United Arab Emirates',
    description:
      'Primary pharma market research in UAE: HCP surveys, advisory boards, payer research, brand tracking, and KOL mapping across DHA, DOH, and MOHAP regulatory contexts.',
    provider: {
      '@type': 'Organization',
      name: 'BioNixus',
      url: 'https://www.bionixus.com',
    },
    areaServed: { '@type': 'Country', name: 'United Arab Emirates' },
    offers: { '@type': 'Offer', priceCurrency: 'USD', priceRange: '$18,000–$120,000' },
  },
  buildBreadcrumbSchema([
    { name: 'Home', href: '/' },
    { name: 'Pharmaceutical Market Research UAE', href: '/uae-pharmaceutical-market-research' },
  ]),
  buildFAQSchema(faqItems),
];

export default function UaePharmaceuticalMarketResearch() {
  return (
    <div className="min-h-screen bg-background">
      <Helmet>
        <title>Pharmaceutical Market Research UAE | Pharma Research Company Dubai — BioNixus</title>
        <meta
          name="description"
          content="Expert pharmaceutical market research in UAE: HCP surveys across DHA, DOH and MOHAP, payer and formulary research, advisory boards, brand tracking. Bilingual Arabic/English field teams."
        />
        <link rel="canonical" href="https://www.bionixus.com/uae-pharmaceutical-market-research" />
        {jsonLd.map((schema, i) => (
          <script key={i} type="application/ld+json">
            {JSON.stringify(schema)}
          </script>
        ))}
      </Helmet>

      <Navbar />
      <main>
        <BreadcrumbNav
          items={[
            { name: 'Home', href: '/' },
            { name: 'Pharmaceutical Market Research UAE', href: '/uae-pharmaceutical-market-research' },
          ]}
        />

        {/* Hero */}
        <section className="py-16 bg-gradient-to-r from-primary to-primary/80 text-primary-foreground">
          <div className="container-wide max-w-5xl mx-auto">
            <h1 className="text-4xl md:text-5xl font-display font-semibold mb-4">
              Pharmaceutical Market Research in UAE
            </h1>
            <p className="text-lg text-primary-foreground/90 leading-relaxed max-w-3xl">
              Decision-ready pharma research across DHA, DOH, and MOHAP regulatory contexts. BioNixus helps commercial,
              medical, and market access teams understand UAE prescribing dynamics, formulary access pathways, and payer
              evidence requirements from Dubai to Abu Dhabi to the Northern Emirates.
            </p>
          </div>
        </section>

        {/* Market context */}
        <section className="py-12">
          <div className="container-wide max-w-5xl mx-auto space-y-5 text-muted-foreground leading-relaxed">
            <h2 className="text-3xl font-display font-semibold text-foreground">
              UAE pharmaceutical market: context and scale
            </h2>
            <p>
              The UAE is the second-largest pharmaceutical market in the GCC, valued at approximately $4.5 billion in
              2024 (IQVIA/Fitch BMI estimates) and growing at 6–8% annually. Dubai accounts for roughly 55% of total
              market value driven by its position as the regional headquarters hub for multinational pharma companies —
              Pfizer, Novartis, Roche, AstraZeneca, Novo Nordisk, Boehringer Ingelheim, and more than 30 other
              multinationals operate their MENA or GCC headquarters from Dubai Healthcare City (DHCC) or the mainland
              business districts.
            </p>
            <p>
              Abu Dhabi constitutes approximately 35% of market value, with a distinctive payer architecture centred on
              mandatory health insurance through Daman (formerly HAAD insurance), which covers approximately 3.5 million
              Abu Dhabi residents. The Abu Dhabi DOH formulary determines reimbursement coverage for this insurance pool
              and is a critical market access gateway for any drug seeking Abu Dhabi penetration. Northern emirates
              (Sharjah, Ajman, Ras Al Khaimah, Fujairah, Umm Al Quwain) represent the remaining 10% of market value and
              operate under MOHAP federal jurisdiction.
            </p>
            <p>
              UAE is also the GCC's most developed private healthcare market, with approximately 50% of all hospital
              capacity privately operated. Key private hospital networks — Mediclinic Middle East, Cleveland Clinic Abu
              Dhabi, Aster DM Healthcare, NMC Health, American Hospital Dubai, Burjeel Holdings — employ large
              specialist physician workforces that function as primary commercial targets for pharmaceutical companies.
              These institutions have their own P&amp;T committees and internal formulary governance, adding a third
              tier of access complexity beyond public payer and federal regulatory approval.
            </p>
          </div>
        </section>

        {/* Regulatory tripartite */}
        <section className="py-12 bg-muted/20">
          <div className="container-wide max-w-5xl mx-auto space-y-5 text-muted-foreground leading-relaxed">
            <h2 className="text-3xl font-display font-semibold text-foreground">
              UAE's tripartite regulatory structure
            </h2>
            <p>
              Understanding UAE pharmaceutical research requires understanding that the UAE operates three parallel health
              regulatory authorities with overlapping and sometimes conflicting drug formulary jurisdiction:
            </p>
            <div className="grid md:grid-cols-3 gap-5 mt-4">
              <div className="rounded-xl border border-border bg-card p-5">
                <h3 className="font-semibold text-foreground mb-2">DHA — Dubai Health Authority</h3>
                <p className="text-sm text-muted-foreground leading-relaxed">
                  Regulates healthcare facilities, professionals, and drug access in Dubai. The DHA Essential Medicines
                  List and Drug Formulary govern reimbursement coverage for approximately 3.7 million Dubai residents
                  under mandatory insurance. DHA Health Economics Department evaluates cost-effectiveness evidence for
                  high-cost drugs.
                </p>
              </div>
              <div className="rounded-xl border border-border bg-card p-5">
                <h3 className="font-semibold text-foreground mb-2">DOH — Abu Dhabi Department of Health</h3>
                <p className="text-sm text-muted-foreground leading-relaxed">
                  Formerly HAAD (Health Authority Abu Dhabi). Regulates healthcare in Abu Dhabi emirate. The Daman
                  National Health Insurance scheme covers mandatory insurance for Abu Dhabi residents with formulary
                  linked to DOH Essential Medicines List. Outcomes-based risk-sharing pilots are emerging under DOH
                  leadership.
                </p>
              </div>
              <div className="rounded-xl border border-border bg-card p-5">
                <h3 className="font-semibold text-foreground mb-2">MOHAP — Ministry of Health and Prevention</h3>
                <p className="text-sm text-muted-foreground leading-relaxed">
                  Federal regulator covering drug registration (national pricing and marketing authorisation), and health
                  oversight in Northern Emirates (Sharjah, Ajman, RAK, Fujairah, UAQ). MOHAP national drug registration
                  is required before DHA or DOH formulary applications. Drug pricing is set at federal level by the
                  MOHAP Drug Pricing Committee.
                </p>
              </div>
            </div>
            <p>
              Pharmaceutical companies must plan access strategies separately for Dubai, Abu Dhabi, and the Northern
              Emirates. A price agreed at federal MOHAP level may still require separate cost-effectiveness submissions
              to DHA and DOH formulary committees. BioNixus designs market access research that captures payer and
              formulary decision-maker perspectives from all three zones in a single integrated study design.
            </p>
          </div>
        </section>

        {/* Research capabilities */}
        <section className="py-12">
          <div className="container-wide max-w-5xl mx-auto space-y-5 text-muted-foreground leading-relaxed">
            <h2 className="text-3xl font-display font-semibold text-foreground">
              UAE pharmaceutical research capabilities
            </h2>
            <p>
              BioNixus delivers the full spectrum of primary research for pharmaceutical strategy teams operating in UAE:
            </p>
            <div className="grid md:grid-cols-2 gap-5 mt-2">
              {[
                {
                  title: 'HCP quantitative surveys',
                  body: 'Online surveys with verified DHA/DOH/MOHAP-licensed physicians across Dubai, Abu Dhabi, and Northern Emirates. Typical n = 50–150 per specialty. Specialty panels available for general practitioners, internists, cardiologists, endocrinologists, oncologists, neurologists, and more.',
                },
                {
                  title: 'KOL mapping and IDI programmes',
                  body: 'Systematic identification of UAE Key Opinion Leaders by specialty, institutional affiliation, and publication/conference influence. IDI series of 8–15 structured interviews, 60 minutes, to capture clinical and commercial opinion from top-tier prescribers and formulary influencers.',
                },
                {
                  title: 'Payer and market access research',
                  body: 'Qualitative interviews with DHA formulary officials, DOH/HAAD insurance specialists, Daman medical directors, and private insurer representatives (AXA Gulf, MetLife MENA, Allianz Care). Evidence requirement mapping for formulary dossier development.',
                },
                {
                  title: 'Advisory boards and expert panels',
                  body: 'Structured advisory forums with 6–12 UAE specialists. DHCC (Dubai Healthcare City) venues available. Bilingual moderation (Arabic/English). 4–6 week recruitment-to-delivery timeline for most specialty areas.',
                },
                {
                  title: 'Brand tracking and awareness studies',
                  body: 'Longitudinal 2–3 wave trackers measuring physician awareness, consideration, prescribing intent, and promotional equity. 75–120 respondents per wave, trackable against GCC-wide benchmarks. Quarterly or semi-annual wave scheduling.',
                },
                {
                  title: 'Patient chart review and RWE',
                  body: 'Structured chart review at UAE hospitals with ethics committee approval. Treatment pattern analysis, time-to-diagnosis, line-of-therapy data, and outcomes measurement. Supports formulary dossier development and brand positioning for UAE payers.',
                },
              ].map(({ title, body }) => (
                <article key={title} className="rounded-xl border border-border bg-card p-5">
                  <h3 className="font-semibold text-foreground mb-2">{title}</h3>
                  <p className="text-sm text-muted-foreground leading-relaxed">{body}</p>
                </article>
              ))}
            </div>
          </div>
        </section>

        {/* Key therapy areas */}
        <section className="py-12 bg-muted/20">
          <div className="container-wide max-w-5xl mx-auto space-y-5 text-muted-foreground leading-relaxed">
            <h2 className="text-3xl font-display font-semibold text-foreground">
              Key therapy areas in UAE pharma research
            </h2>
            <p>
              UAE's disease profile reflects both the Gulf's high-prevalence metabolic conditions and the international
              patient population drawn to the country's world-class private healthcare system:
            </p>
            <ul className="list-disc pl-6 space-y-3">
              <li>
                <strong className="text-foreground">Diabetes and metabolic disease:</strong> UAE adult diabetes
                prevalence is approximately 19% (IDF 2023), one of the highest globally. GLP-1 receptor agonist adoption,
                SGLT-2 inhibitor market share, and insulin optimisation are active research areas. Ramadan fasting
                management protocols are a UAE/GCC-specific research topic relevant to all glucose-lowering therapies.
              </li>
              <li>
                <strong className="text-foreground">Oncology:</strong> Tawam Hospital (Abu Dhabi) is the GCC's leading
                referral oncology centre. American Hospital Dubai and Burjeel Medical City also run significant oncology
                programmes. UAE is a priority market for CAR-T, targeted therapies, and immunotherapy launches given
                the private payer coverage and high-income patient population.
              </li>
              <li>
                <strong className="text-foreground">Cardiovascular and hypertension:</strong> UAE ranks among the
                highest globally for cardiovascular disease mortality. Multinational pharmaceutical companies use UAE
                as a reference market for GCC commercial launch given its private payer ecosystem and price-premium
                tolerance.
              </li>
              <li>
                <strong className="text-foreground">Respiratory (asthma and COPD):</strong> Dust exposure, air quality,
                and sedentary lifestyle drive respiratory disease burden. Biologic therapy (dupilumab, mepolizumab,
                benralizumab) access requires DHA and DOH prior-authorisation — a key focus area for market access
                research.
              </li>
              <li>
                <strong className="text-foreground">Rare diseases:</strong> UAE has a relatively well-funded rare
                disease support ecosystem through DOH programmes and patient advocacy groups. Enzyme replacement
                therapy, gene therapy, and orphan drug launches use UAE as an early GCC market entry point due to
                formulary responsiveness and private payer coverage.
              </li>
              <li>
                <strong className="text-foreground">Mental health:</strong> Growing investment in UAE mental health
                services (National Strategy for Wellbeing 2031) is creating new pharmaceutical market opportunities
                for antidepressants, antipsychotics, and ADHD treatments. Stigma research and HCP awareness studies
                are emerging priorities.
              </li>
            </ul>
          </div>
        </section>

        {/* Proof metrics */}
        <section className="py-12">
          <div className="container-wide max-w-5xl mx-auto">
            <h2 className="text-3xl font-display font-semibold text-foreground mb-6 text-center">
              UAE research at a glance
            </h2>
            <div className="grid md:grid-cols-3 gap-6 text-center">
              <div className="rounded-xl border border-border bg-card p-6">
                <p className="text-4xl font-display font-bold text-primary mb-2">3</p>
                <p className="text-sm text-muted-foreground">Regulatory zones covered: DHA, DOH, MOHAP</p>
              </div>
              <div className="rounded-xl border border-border bg-card p-6">
                <p className="text-4xl font-display font-bold text-primary mb-2">15,000+</p>
                <p className="text-sm text-muted-foreground">Licensed physicians in UAE HCP panel</p>
              </div>
              <div className="rounded-xl border border-border bg-card p-6">
                <p className="text-4xl font-display font-bold text-primary mb-2">4–7 wks</p>
                <p className="text-sm text-muted-foreground">Typical survey delivery (briefing to report)</p>
              </div>
            </div>
          </div>
        </section>

        {/* PDPL compliance */}
        <section className="py-12 bg-muted/20">
          <div className="container-wide max-w-5xl mx-auto space-y-5 text-muted-foreground leading-relaxed">
            <h2 className="text-3xl font-display font-semibold text-foreground">
              UAE data protection compliance (PDPL 2021)
            </h2>
            <p>
              UAE's Personal Data Protection Law (Federal Decree-Law No. 45 of 2021, effective September 2022) establishes
              consent, purpose limitation, and data residency requirements for personal data processing. For pharmaceutical
              market research, this means:
            </p>
            <ul className="list-disc pl-6 space-y-2">
              <li>
                HCP respondents must provide informed consent before participation, including consent for recording if
                applicable. BioNixus recruitment screeners include PDPL-compliant consent language.
              </li>
              <li>
                Patient research requires ethics committee approval from the relevant authority (DHA Research Ethics
                Committee for Dubai studies, DOH Ethics Committee for Abu Dhabi studies) and written patient consent.
              </li>
              <li>
                Respondent personal data (name, Emirates ID, licence number) is processed under data processor agreements
                and not retained beyond the study period without explicit consent.
              </li>
              <li>
                Data residency: research data collected in UAE is stored on BioNixus's ISO 27001-compliant infrastructure.
                Cross-border data transfer to pharma clients is covered by data processing agreements referencing
                adequate protection standards.
              </li>
            </ul>
            <p>
              BioNixus provides clients with a PDPL compliance summary for each UAE study as part of the final
              deliverable package, supporting corporate data governance documentation requirements.
            </p>
          </div>
        </section>

        {/* Internal links */}
        <section className="py-10">
          <div className="container-wide max-w-5xl mx-auto">
            <h2 className="text-2xl font-display font-semibold text-foreground mb-5">Related UAE and GCC research</h2>
            <div className="flex flex-wrap gap-3">
              {[
                { label: 'UAE market access research', to: '/uae-market-access-research' },
                { label: 'UAE pricing and reimbursement strategy', to: '/uae-pricing-reimbursement-strategy' },
                { label: 'Specialist physician panel UAE', to: '/specialist-physician-panel-uae' },
                { label: 'Pharma fieldwork UAE', to: '/pharma-fieldwork-uae' },
                { label: 'Diabetes market research UAE', to: '/diabetes-market-research-uae' },
                { label: 'Healthcare market research agency GCC', to: '/healthcare-market-research-agency-gcc' },
              ].map(({ label, to }) => (
                <Link
                  key={to}
                  to={to}
                  className="rounded-lg border border-border bg-card px-4 py-2 text-sm font-medium text-foreground hover:bg-muted"
                >
                  {label}
                </Link>
              ))}
            </div>
          </div>
        </section>

        {/* FAQ */}
        <section className="py-12 bg-muted/20">
          <div className="container-wide max-w-5xl mx-auto">
            <h2 className="text-3xl font-display font-semibold text-foreground mb-6">
              Frequently asked questions
            </h2>
            <div className="space-y-3">
              {faqItems.map((item) => (
                <details key={item.question} className="rounded-xl border border-border bg-card p-5">
                  <summary className="cursor-pointer font-semibold text-foreground">{item.question}</summary>
                  <p className="text-sm text-muted-foreground mt-3 leading-relaxed">{item.answer}</p>
                </details>
              ))}
            </div>
          </div>
        </section>

        {/* CTA */}
        <section className="py-16 bg-primary text-primary-foreground">
          <div className="container-wide max-w-3xl mx-auto text-center space-y-4">
            <h2 className="text-3xl font-display font-semibold">
              Start your UAE pharma research programme
            </h2>
            <p className="text-primary-foreground/90">
              Share your objective and target audience. BioNixus will propose a UAE-specific research design, cost
              estimate, and timeline within 48 hours.
            </p>
            <Link
              to="/contact"
              className="inline-block bg-primary-foreground text-primary font-semibold px-8 py-3 rounded-lg hover:bg-primary-foreground/90 transition-colors"
            >
              Request a UAE research proposal
            </Link>
          </div>
        </section>
      </main>
      <Footer />
    </div>
  );
}
